US urges tighter standards for HBV (Hepatitis B virus) screening
This article was originally published in Clinica
Executive Summary
An FDA advisory panel last week urged the agency to require more rigorous screening standards for the presence of the Hepatitis B virus (HBV) in US blood supplies. Voting unanimously, the panel recommended that the FDA alter its lot release specifications by lowering the limits of HBV detection that the lot must achieve.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.